Mohamed Elsaid on The Role of Hyperlipidemia in Thrombogenesis
Mohamed Elsaid, Veterinary Surgeon at Canadian Veterinary Hospital, shared on LinkedIn:
”Hyperlipidemia in Cushing’s Syndrome and Its Role in Thrombogenesis
Hyperlipidemia is a common but often underestimated metabolic consequence of Cushing’s syndrome, and it plays a direct role in the development of thromboembolic disease.
Pathophysiology
Chronic hypercortisolism induces dyslipidemia through multiple mechanisms:
- Increased hepatic VLDL synthesis
- Enhanced lipolysis with redistribution of free fatty acids
- Reduced activity of lipoprotein lipase
- Insulin resistance contributing to altered lipid metabolism
This typically results in:
– Marked hypertriglyceridemia
– Elevated total cholesterol
– Lipemic or grossly turbid serum samples (as seen clinically)
– Link Between Hyperlipidemia and Thrombosis
Hyperlipidemia contributes to thrombogenesis by:
- Increasing blood viscosity
- Promoting endothelial dysfunction
- Enhancing platelet activation and aggregation
- Reducing fibrinolytic activity via increased PAI-1
- Upregulating procoagulant factors (Factors VIII, IX, XI)
These effects act synergistically with cortisol-induced:
Antithrombin III suppression
Decreased protein C and S activity
The result is a profound hypercoagulable state.
Clinical Implications
Patients with Cushing’s syndrome are predisposed to:
Venous thromboembolism (VTE)
Pulmonary thromboembolism
Microthrombi affecting renal, hepatic, and pulmonary perfusion
Hyperlipidemia should therefore be viewed as a pathologic contributor, not merely a biochemical abnormality.
Clinical Take-Home Messages
– Lipemic serum in Cushing’s patients is a red flag
– Routine lipid profiling should be part of endocrine case monitoring
– Thrombotic risk assessment is essential, especially in severe or untreated cases
– Early intervention may reduce morbidity and mortality.”
Stay updated with Hemostasis Today.
-
Jun 24, 2026, 09:29Advancing Women’s Health Through Collaboration with Jean Hailes for Women’s Health – Stroke Foundation
-
Jun 24, 2026, 09:18The Lasting Immunological Footprint of VITT – JTH
-
Jun 24, 2026, 09:09Umberto Pensato: Dedicated Funding Pathways for Stroke Research in Italy
-
Jun 24, 2026, 09:00Danny Gaskin: BBTS 2026 and the Evolving Role of Transfusion in Maternity Care
-
Jun 24, 2026, 07:46Wolfgang Miesbach: WFH’s First AAV Gene Therapy Chapter Marks a New Era in Hemophilia Care
-
Jun 24, 2026, 06:42Deepthi Krishna: World Blood Donor Day 2026 Celebrations at Rela Hospital
-
Jun 24, 2026, 03:36Ana Pedrero Gil: A New Approach to Post-Tonsillectomy Hemorrhage
-
Jun 24, 2026, 02:59Melissa Hollo: Making Early Anemia Detection the Standard of Care
-
Jun 24, 2026, 02:51Bruno Pougault: The Thin Line Between Bleeding and Clotting